Background. Epidemiologic and experimental evidence suggests that individuals with diabetes are at increased risk of infection. We sought to examine the association of diabetes and insulin therapy with hospitalization for infection and 28-day mortality.
Diabetes and infection are common, expensive, and often concurrent conditions [1] [2] [3] . Infection can lead to sepsis, which is organ dysfunction due to a dysregulated host response to infection. Although the pathophysiology and treatment of diabetes has been intensively studied, the association between diabetes, infection, and mortality risk has not been fully elucidated. Current research suggests that diabetes is a risk factor for infection through various host-and organism-specific mechanisms. For example, hyperglycemia is associated with deleterious effects on granulocyte chemotaxis, phagocytosis, and adherence [4] [5] [6] . In addition, individuals with diabetes may also experience increased risk of infection due to local tissue ischemia resulting from vascular insufficiency, peripheral or autonomic diabetic neuropathy, colonization by organisms such as methicillin-resistant Staphylococcus aureus, and molecular mechanisms (eg, increased pathogen expression of adhesion molecules in response to high concentrations of glucose) [7] [8] [9] [10] .
The notion that diabetes may be a risk factor for infection is supported by several population-based studies [11] [12] [13] [14] . Whether infected or septic patients with diabetes are more likely to die than their counterparts without diabetes, however, is not clear. The literature is conflicted, with some studies finding harm [15] [16] [17] [18] , others no influence [19] [20] [21] [22] , and still others a possible protective influence of diabetes on outcomes [23] [24] [25] . One explanation for the diversity of findings is methodologic issues in the studies to date. For example, the diabetes-mortality relationship has generally been assessed in studies comprising patients presenting to the hospital for care. The role of chronic insulin therapy in the association between diabetes and infection has also not been examined in detail, although prior studies suggest an association of insulin use with infections of the skin or soft tissues [26, 27] . Furthermore, insulin use may function as a marker for advanced disease and could affect infection hospitalization risk as well as outcomes.
To address the limitations of prior investigations and to better define the relationship between diabetes, incidence of infection hospitalization, and mortality risk after infection, we conducted a longitudinal investigation using data from the population-based REasons for Geographic and Racial Differences in Stroke (REGARDS) cohort. We hypothesized that community-dwelling adults with diabetes would be more likely than those without diabetes to be hospitalized with infection and that, once hospitalized for an infection, individuals with diabetes would have increased mortality. We also hypothesized that participants with diabetes receiving insulin therapy would have additional increased risk of infection hospitalization and mortality risk.
MATERIALS AND METHODS

Study Design
We used data from the REGARDS study, one of the largest population-based cohorts of community-dwelling adults in the United States [28] . REGARDS includes 30 239 black or white adults aged ≥45 years from the 48 contiguous US states and the District of Columbia [28] . The study oversampled blacks and individuals living in the Southeastern United States, with 21% of the cohort originating from the coastal plains of North Carolina, South Carolina, and Georgia (the "stroke buckle"), 35% from the remainder of North Carolina, South Carolina, and Georgia plus Tennessee, Mississippi, Alabama, Louisiana, and Arkansas (the "stroke belt"), and 44% from other states ("non-stroke belt"). REGARDS participants are 42% black and 45% male, with 69% aged >60 years at the time of enrollment.
The REGARDS study enrolled participants between 2003 and 2007, obtaining baseline data for each participant using phone interview and an in-person evaluation. REGARDS contacted study participants at 6-month intervals by telephone, identifying the date, location, and attributed reason for all hospitalizations. If the participant died, the study team reviewed death certificates, autopsy reports, and medical records and interviewed proxies to ascertain the circumstances of the participant's death. The REGARDS study was approved by the institutional review boards of participating institutions, and all participants provided verbal consent before the telephone interview and written informed consent before the in-home study visit.
Identification of Serious Infection and Sepsis Events
We identified participants experiencing hospitalizations for serious infections, based on criteria introduced by Angus et al [29] (including admissions to the emergency department or hospital for infection). We searched all reported hospitalizations, and 2 trained abstractors independently reviewed all relevant medical records to confirm infection as a reason for hospitalization [29] . Sepsis events were defined as presentation with an infection plus ≥2 systemic inflammatory response syndrome criteria [30] , based the worst vital signs and laboratory test values observed during the initial 28 hours of hospitalization. We defined severe sepsis as sepsis with dysfunction of ≥1 organ and septic shock as sepsis with hypotension refractory to fluid administration and/or the use of vasopressors, both according to previously published criteria for the Sepsis-related Organ Failure Assessment (SOFA) score [31] . Initial review of 1349 hospital records indicated excellent interrater agreement for presence of a serious infection (κ = 0.92). We included hospitalization events during the follow-up period, from 5 February 2003 through 31 December 2012. We also determined all-cause mortality risk within 28 days of infection, with deaths through 28 January 2013 included in this analysis.
Primary Exposure and Participant Characteristics
Participant characteristics were determined at the time of REGARDS enrollment. The primary exposure for this study was history or presence of diabetes. Diabetes was defined as a fasting glucose level ≥126 mg/L (or a glucose level ≥200 mg/L for those not fasting), the use of insulin or oral hypoglycemic agents, or self-reported history of diabetes. REGARDS study procedures did not permit differentiation between types 1 and 2 diabetes. We also defined participants with diabetes as users or nonusers of insulin therapy.
Demographic characteristics included age, sex, race, region, and self-reported annual household income and education. Region was defined as stroke buckle, stroke belt, or nonbelt. Health behaviors included smoking status and alcohol use. Smoking status was classified as current, former, or never. Alcohol use categories included none, moderate (1 drink per day for women or 2 drinks per day for men), and heavy (>1 drink per day for women and >2 drinks per day for men) [32] . We also identified body mass index and classified participants into standard categories: normal/underweight (<25 kg/m 2 ), overweight (25-30 kg/m 2 ), or obese (>30 kg/m 2 ) [33] . Chronic conditions and biomarkers included lung disease, statin use, dyslipidemia, hypertension, myocardial infarction (MI), stroke, chronic kidney disease, and elevated high-sensitivity C-reactive protein (CRP). Based on the initial medication inventory, we defined use of β-agonists, leukotriene inhibitors, inhaled corticosteroids, combination inhalers, ipratropium, cromolyn, aminophylline, or theophylline as a surrogate for chronic lung disease. Statin use was defined in a similar manner, with specific statins reported by subjects including atorvastatin, fluvastatin, lovastatin, pravastatin, rosuvastatin, and simvastatin. Dyslipidemia was defined as low-density lipoprotein cholesterol levels >130 mg/dL or the use of lipid-lowering medications. Criteria for hypertension included systolic blood pressure ≥140 mm Hg, diastolic blood pressure ≥90 mm Hg, or use of antihypertensives. MI was defined as a self-reported history or baseline electrocardiographic evidence of MI. Participants self-reported history of prior stroke or transient ischemic attacks. Chronic kidney disease was defined as an estimated glomerular filtration rate <60 mL/min/1.73m 2 .
Serum creatinine was assayed using colorimetric reflectance spectrophotometry (Ortho Vitros Clinical Chemistry System 950IRC; Johnson & Johnson Clinical Diagnostics), and the estimated glomerular filtration rate was based on the Chronic Kidney Disease Epidemiology Collaboration equation [34] . Elevated CRP levels were defined as those >3.0 mg/dL; CRP was assayed using particle-enhanced immunonephelometry (N High-sensitivity CRP; Siemens). Among participants hospitalized for infection, we also obtained hospitalization characteristics. We determined admission destination (intensive care unit or floor) and length of stay for events resulting in hospital admission. Infection type was also identified, based on available clinical documentation. Participants were additionally classified based on admission from or discharge to a nursing, assisted care, or rehabilitation facility.
Data Analysis
We compared participant characteristics between participants with or without diabetes, using t tests or nonparametric Wilcoxon rank-sum tests for continuous variables and Pearson χ 2 tests for categorical variables. Among participants hospitalized for infection, we also compared baseline and discharge characteristics using exact and nonparametric tests, as appropriate. We fit Cox proportional hazards models to assess the association of diabetes with rates of infection, including time from enrollment to first hospitalization as the outcome. Participants were censored at loss to follow-up, death, or 31 December 2012. Sequential models were constructed, with adjustment for demographics and health behaviors, chronic conditions, and body mass index class. We verified the proportional hazards assumption using Schoenfeld residuals and tests of the interaction with the logarithm of time. We present a complete case analysis but also performed the analysis using multiple imputation with chained equations to account for missing participant characteristic values (data not shown).
To assess the association of diabetes with mortality risk during hospitalization or within 28 days of hospitalization for infection or sepsis, we fit logistic regression models. Models were adjusted for factors associated with both diabetes and mortality, in addition to SOFA score. Participants with missing follow-up information after hospitalization who did not die during the infection event were excluded from mortality analyses. We performed a sensitivity analysis in which we used logistic regression models fit with generalized estimating equations to assess mortality among all infection hospitalizations (including those beyond the first event), adjusting for the same characteristics as outlined above. We performed an additional sensitivity analysis in which we limited mortality analyses to participants with sepsis or severe sepsis. We also constructed models for infection hospitalization risk and mortality with the primary exposure classified into 3 groups: no diabetes, diabetes with no insulin, and diabetes with insulin. We conducted all analyses using Stata 13.1 software (StataCorp).
RESULTS
A total of 30 239 patients were enrolled in REGARDS, of whom 29 683 had complete follow-up information. Among participants with complete follow-up, 7375 (24.9%) were identified as having diabetes at baseline (Figure 1 ). Compared with participants without diabetes, those with diabetes were older and more likely to be female, black, from the stroke belt, have a lower level of education and income, be overweight, and have a higher comorbid burden (Table 1 ). In addition, 1685 participants with diabetes (22.9%) were receiving insulin at the time of baseline enrollment. Participants with diabetes receiving insulin differed from those who were not in that they were more likely to be black, have lower education and income, and have an increased comorbid burden (eTable 1). During the study period, there were 2593 first infection hospitalization events (8.7%) and 3411 total events. The median follow-up time was 6.6 years (interquartile range, 5.1-8.1 years) for censored participants and 3.6 years (1.8-5.5 years) for those hospitalized with infection. Among participants hospitalized for infection, those with diabetes were younger and more likely to be black, have skin or soft-tissue infections, meet criteria for severe sepsis, be discharged to a nursing home, have a higher SOFA score, and have longer stay when admitted (Table 2 ). For participants with diabetes hospitalized for infection, those using insulin were more likely to be black, have infections classified as skin or soft-tissue infection, sepsis, or catheter related, meet criteria for severe sepsis, be discharged to a nursing home, and have a higher SOFA score with a longer hospital stay (eTable 2).
Participants with diabetes had an increased hazard of hospitalization for infection than those without diabetes (Table 3 ; Figure 2A ). After adjustment for demographic characteristics, health behaviors, and chronic conditions, the association between diabetes and infection hazard remained (Table 3) . However, the odds of death within 28 days after an infection hospitalization did not differ between those with and those without diabetes (Table 4) . In a sensitivity analysis including infection events beyond the first, we observed similar results when comparing the odds of death within 28 days between participants with diabetes and those without (unadjusted odds ratio [OR], 1.21 [95% confidence interval (CI), .95-1.54; adjusted OR, 0.85 [.64-1.13]). We also examined mortality risk for first infection events, restricting the population to those meeting the criteria for sepsis or severe sepsis, and we obtained similar results (eTable 3). Finally, performing the analysis using multiple imputation to account for missing values produced similar associations (data not shown).
When we tested our secondary hypothesis about the differential effects among participants with diabetes on insulin therapy, we found that participants with diabetes receiving insulin had Figure 2B ) However, once again, there was no increase in the odds of death within 28 days for participants receiving insulin (OR, 1.07; 95% CI, .67-1.71) ( Table 3 ; eTable 3).
DISCUSSION
Our observations affirm that diabetes is associated with increased hazard of infection hospitalization. We also found that participants receiving insulin therapy experienced a more pronounced infection risk. However, somewhat surprisingly, neither diabetes nor insulin use was associated with increased 28-day mortality after infection. The current study builds on prior efforts by linking robust baseline data with infection incidence and outcomes in a large cohort of community-dwelling adults. Our results suggest a need for improved control of risk factors for infection among individuals with diabetes, as well as continuing research on differential infection mechanisms during diabetic conditions. There are a number of plausible explanations for increased infection among participants with diabetes. Diabetic complications, such as neuropathy, microvascular damage, and glycosuria, are recognizable contributors to the propensity for skin, soft-tissue, and urinary tract infections [8, 9] . Impaired immunologic function (reduced neutrophil and macrophage activity or T-lymphocyte subset alteration) in the presence of hyperglycemia may also be responsible for increased risk of pneumonia [15, 18] . Complications aside, diabetic infections occur in an altered physiologic milieu, where the intrinsic properties of the host have been altered by repeated or continual hyperglycemia and/or metabolic syndrome. Concentrations and effects of metabolic mediators other than insulin with in vivo effects on immunologic function (eg, adipokines such as resistin and leptin) may also be altered in these individuals [35, 36] .
We also showed that participants with diabetes receiving insulin therapy experience an even higher risk of infection than those not receiving insulin. This finding could be explained by increased severity of disease, a mechanism directly related to insulin, or increased event detection. The mechanisms outlined above that might explain why diabetes is generally associated with increased risk of infection may be more pronounced in the population receiving insulin therapy. Injecting insulin regularly could also have increased the occurrence or severity of skin or soft-tissue infections by allowing pathogenic organisms to more easily cross the dermal barrier [26, 27] . However, it is important to consider alternative explanations not directly related to the disease. For instance, the population receiving insulin may have been more closely monitored for infectious complications, thus reducing the threshold for admission by a care provider. Further research should examine the association between insulin use and infection in greater detail to better understand potential mechanisms.
Our finding of similar infection-and sepsis-associated mortality risk, regardless of diabetes status, fits with findings of prior studies showing that diabetes is not related to in-hospital infection or sepsis-related mortality [19, 21, 22] . Interesting arguments have been advanced regarding the effect of diabetes during an infection, which may contribute to the observations of Schuetz et al [37] and Whitcomb et al [38] , in that these studies found diabetes to be protective. Authors of a large epidemiologic study using the National Hospital Discharge Survey found that patients with diabetes were less likely to develop acute respiratory distress syndrome and postulated that this difference could be due to a blunted inflammatory response [39] . In a similar manner, the low-level of chronic inflammation associated with obesity and hyperglycemia may prime the body for oxidant stress associated with sepsis [40] . The same metabolic syndrome and obesity that is commensurate with rising rates of type 2 diabetes in the United States may then provide a caloric reserve that exerts a protective effect through an intensive care unit stay [41, 42] .
As findings of an observational, population-based study, these results in and of themselves do not yield insight into the underlying mechanisms linking diabetes with infection and sepsis. However, our study improves on prior efforts, which were unable to combine longitudinal infection incidence with granular acute infection event data. These results offer further grounds for investigating why diabetes may not contribute to increased infection or sepsis mortality, such as through diminution of the immunologic or inflammatory cascade or through greater caloric reserve to survive critical illness. They also reinforce the need for proactive community-based interventions to reduce the risk of infection, such as regular preventive diabetic foot and skin checks, with adequate wound care. Our study has several notable strengths, including a large sample size, standardized infection hospitalization detection and adjudication, comprehensive baseline participant data, and a follow-up period of nearly 10 years. However, our results must be interpreted in light of several important limitations. The REGARDS cohort enrolled black and white community-dwelling adults aged ≥45 years, which limits the generalizability of our results. For instance, our findings may not generalize to younger individuals or those of Hispanic ethnicity. Baseline diabetes status was ascertained, but we were not able to identify incident diabetes during the course of the follow-up period. However, it is unclear whether or not this misclassification would be differential with respect to infection hazard. We also were not able to obtain data on glycemic control or diabetes duration. Despite a comprehensive approach to identification of infection events, we may have failed to capture all hospitalizations. Further efforts should examine this association and collect more granular details pertaining to diabetes, as well as factors affecting hospitalization and postdischarge outcomes.
In conclusion, using data from one of the largest population-based cohort studies in the United States, we found that diabetes is associated with a higher risk of hospitalization for infection, but those with diabetes are no more likely to die from these conditions within 28 days of hospitalization. Furthermore, individuals with diabetes on insulin therapy are at higher risk of acquiring infection but are similarly not at increased risk of death. Our findings highlight the need for improved control of infection risk factors among individuals with diabetes and further research to explain why diabetes may not be associated with poor infection outcomes.
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